Organigram reports spike in sales, revenue from Motif acquisition

Organigram Reports Second Quarter Fiscal 2025 Results

TORONTO — Organigram Global Inc. announced its results for the second quarter ended March 31, 2025 (“Q2 Fiscal 2025”). The Q2 Fiscal 2025 results include a full quarter of consolidated financials from the Company’s acquisition of Motif Labs Ltd.\ on December 6, 2024. Q2 fiscal 2025 highlights Gross revenue increased 79% to $102.8 million from $57.4 million in the same prior year period. Net revenue increased 74% to $65.6 million from $37.6 mill…

Organigram reports spike in sales, revenue from Motif acquisition

Organigram Global Inc. brought in $42.5 million in net income for the three months ending March 31, 2025 (Q2 2025) from $102.8 million in gross... The post Organigram reports spike in sales, revenue from Motif acquisition appeared first on StratCann.

Organigram reports record Q2 fiscal 2025 results

Organigram (TSX:OGI) announced its financial results for its Q2 of fiscal 2025, showing off notable growth across various metrics Gross revenue increased by 79 per cent to $102.8 million, up from $57.4 million in the same period last year Net revenue rose by 74 per cent to $65.6 million, compared to $37.6 million in the prior year period Organigram stock (TSX:OGI) last traded at C$1.64 Organigram (TSX:OGI) announced its financial results for its…

Organigram Q2 Was Better Than Expected

Organigram Reports Record Second Quarter Fiscal 2025 Results Record gross revenue of $102.8 million and record net revenue of $65.6 million Adjusted EBITDA¹ of $4.9 million Net income of $42.5 million Increase in anticipated Motif cost synergies to $15 million from $10 million Total cash position of $83.4 million² and negligible debt TORONTO–(BUSINESS WIRE)–Organigram Global […]